DCM
INO icon

Dialectic Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Dialectic Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,083
Closed -$174K – 70
2016
Q4 		$174K Buy
+2,083
New +$188K 0.1% 73
2016
Q3 		– Sell
-4,167
Closed -$462K – 101
2016
Q2 		$462K Sell
4,167
-16,666
-80% -$2.02M 0.15% 86
2016
Q1 		$2.18M Buy
+20,833
New +$1.61M 1.02% 20

Other funds holding INO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dialectic Capital Management's INO Position: Q1 2017 in Review

Dialectic Capital Management sold out of Inovio Pharmaceuticals (INO) in Q1 2017, closing a stake of 2,083 shares — an estimated $174K sold.

Dialectic Capital Management first reported a position in INO in Q1 2016 and held it in 3 quarters. The position peaked at $2.18M in Q1 2016. 106 funds tracked by Wall St. Rank hold INO as of Q1 2017.

  • Dialectic Capital Management reported no remaining Inovio Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Dialectic Capital Management sold 2,083 Inovio Pharmaceuticals shares in Q1 2017, an estimated $174K.
  • Dialectic Capital Management first reported a position in Inovio Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Dialectic Capital Management's Inovio Pharmaceuticals position peaked at $2.18M in Q1 2016.
  • 106 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2017.

Based on Dialectic Capital Management's 13F filing for Q1 2017, filed 11 May 2017.